TG Therapeutics, Inc.

TGTX

$2.50B

Mid Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaNEW YORK374 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Sep 1, 2026

29w

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

2 upcoming, 0 past

⭐Phase 3Next

Ublituximab Phase 3 Results Expected

Sep 1, 2026Ublituximab800

Primary completion for Ublituximab trial (NCT05877963) in Relapsing Multiple Sclerosis

Source

⭐Phase 3

Ublituximab Phase 3 Results Expected

Dec 31, 2026Ublituximab360

Primary completion for Ublituximab trial (NCT07211633) in Relapsing Multiple Sclerosis

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Teriflunomide

Phase 3

Relapsing Multiple Sclerosis (RMS)

Ublituximab

Phase 3

Non-Hodgkins Lymphoma

Ibrutinib

Phase 3

Chronic Lymphocytic Leukemia

Umbralisib

Phase 2

Marginal Zone Lymphoma

Drug Name	Phase	Indication	Designations
Teriflunomide	Phase 3	Relapsing Multiple Sclerosis (RMS)	-
Ublituximab	Phase 3	Non-Hodgkins Lymphoma	-
Ibrutinib	Phase 3	Chronic Lymphocytic Leukemia	-
Umbralisib	Phase 2	Marginal Zone Lymphoma	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

TGTX News